Novartis Pegs Combined Market For Tasigna And Gleevec At $3.5 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says market for chronic myeloid leukemia therapies will be further differentiated pending additional studies of Tasigna.